The US Food and Drug Administration (FDA) approved sarilumab (Kevzara) today for the treatment of polymyalgia rheumatica (PMR) in adults who have had an inadequate response to corticosteroids or could ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

Please provide your email address to receive an email when new articles are posted on . “If providers treating PMR are having difficulty tapering people off steroids without concomitant ...

DEAR DR. ROACH: I was recently diagnosed with polymyalgia rheumatica after weeks of intense muscle pain. I’m a 67-year-old female in otherwise good health. My doctor prescribed prednisone, which ...

PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals today announced that it presented new data from its ongoing Phase 2 clinical trial of its HSD-1 inhibitor, clofutriben (referred to SPI-62 in ...

The approval was based on data from a phase 3 study which included adults with steroid-resistant active PMR who flared on at least 7.5mg per day of prednisone or equivalent during taper. The Food and ...

Background: the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a result, there is no evidence from ...

Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

However, patient-reported scores were not significantly better in the tocilizumab group. Tocilizumab (Actemra) appears to lead to meaningful results in patients with active polymyalgia rheumatica ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I think my 75-year-old husband has polymyalgia rheumatica, ...